Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.34

€0.34

-4.680%
-0.016
-4.680%
-

-

 
28.07.26 / Tradegate WKN: A2H8YL / Symbol: PBMD / Name: Immutep / Stock / Biotechnology & Medical Research / Micro Cap /
Latest predictions
31.05.26
-12.37%
buy
Your prediction

Immutep LTD ADR Stock

Heavy losses for Immutep LTD ADR today as the stock fell by -€0.016 (-4.680%).
So far the community has only identified positive things for Immutep LTD ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Immutep LTD ADR in the next few years

Pros
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Immutep LTD ADR vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Immutep LTD ADR -4.680% -3.448% -6.145% -78.462% -87.077% -83.200% -88.414%
TALI Digital Ltd. - 0.000% -99.444% 0.000% -98.529% 0.000% -96.970%
Invion Ltd 0.000% 0.000% 5.000% -48.148% -47.500% 2000.000% 180.000%
Alterity Therapeutics Ltd. ADR -0.530% -6.533% -9.709% -0.932% 50.000% -0.932% -65.556%

Comments

Buy Immutep LTD ADR
Show more

News

Dr. Reddy's Laboratories Q4 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, soft focus,  Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-pKgbwxVSbyTCu0UzPNe8NL8D.png?st=2023-05-04T16%3A02%3A58Z&se=2023-05-04T18%3A02%3A58Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12%3A13%3A51Z&ske=2023-05-05T12%3A13%3A51Z&sks=b&skv=2021-08-06&sig=%2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg%3D
Dr. Reddy's Laboratories Q4 Earnings Call Highlights

Dr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026